Usefulness of procalcitonin levels in community-acquired pneumonia according to the patients outcome research team pneumonia severity index

Chest

Volumn 128, Issue 4, 2005, Pages 2223-2229

  Masiá, Mar ^a   Gutiérrez, Félix ^a   Shum, Conrado ^a   Padilla, Sergio ^a   Navarro, Juan Carlos ^a   Flores, Emilio ^a   Hernández, Ildefonso ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

Biological markers; Biomarkers; Community acquired pneumonia; Etiology; Outcome; Pneumonia severity index; Predictive scoring system; Procalcitonin; Prognosis

Indexed keywords

BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; PROCALCITONIN;

ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD SAMPLING; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SCORING SYSTEM;

EID: 27144436156     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.4.2223     Document Type: Article

References (24)

1. Simon L, Gauvin F, Anre K, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-217
2. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 2001; 131:595-602
3. Farr BM, Kaiser DL, Harrison BD, et al. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44:1031-1035
4. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433
5. BTS guidelines for the management of community acquired pneumonia in adults. British Thoracic Society Standards of Care Committee. Thorax 2001; 56 (suppl 4):IV1-IV64
6. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28:68-73
7. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607
8. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003; 21:939-943
9. Moulin F, Raymond J, Lorrot M, et al. Procalcitonin in children admitted to hospital with community acquired pneumonia. Arch Dis Child 2001; 84:332-336
10. Toikka P, Irjala K, Juven T, et al. Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000; 19:598-602
11. Korppi M, Remes S, Heiskanen-Kosma T. Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 2003; 35:56-61
12. Whang KT, Steinwald PM, White JC, et al. Serum calcitonin precursors in sepsis and systemic inflammation. J Clin Endocrinol Metab 1998; 83:3296-3301
13. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977-983
14. Castelli GP, Pognani C, Meisner M, et al. Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction. Crit Care 2004; 8:R234-242
15. Hausfater P, Garric S, Ayed SB, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 2002; 34:895-901
16. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118:1344-1354
17. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250
18. Gutiérrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochroinatographic Binax NOW assay for detection of Streptococcus pnewnoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286-292
19. Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin-influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 1997; 35:597-601
20. Oosterheert JJ, Bonten MJ, Hak E, et al. Severe community-acquired pneumonia: what's in a name? Curr Opin Infect Dis 2003; 16:153-159
21. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia: risk factors and follow-up epidemiology. Am J Respir Crit Care Med 1999; 160:923-929
22. Nylen ES, O'Neill W, Jordan MH, et al. Serum procalcitonin as an index of inhalation injury in burns. Horm Metab Res 1992; 24:439-443
23. Nylen ES, Snider RH Jr, Thompson KA, et al. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996; 312:12-18
24. Muller B, Christ-Crain M, Nylen ES, et al. Limits to the use of the procalcitonin level as a diagnostic marker. Clin Infect Dis 2004; 39:1867-1868